DSMB Supports Continuation Of The Phase Iii Clinical Trial Of IluvienTM For Diabetic Macular EdemaTreatment
Oct 1st 2008Drug InformationDiabetes
Global drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FF: PV3) today announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME? (Fluocinolone Acetonide in Diabetic Macular Edema) Study continue under the current protocol, without change.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
